Want to join the conversation?
Biopharmaceutical company $AMGN said European Commission (EC) granted marketing authorization for its Kyprolis drug in combination with lenalidomide and dexamethasone for treating adults with multiple myeloma (incurable blood cancer) who have received at least one prior therapy. EC approved Kyprolis based on data from pivotal Phase 3 aspire trial.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!
$SGY is expected to achieve $6.17 price target in next year, with a minimum target of $3.00, due to the price increase of 27.85% to $6.29 during the last trading session.